BREAKING NEWS....The University of Pittsburgh was selected as one of 56 companies for the Defense Health Agency's Omnibus IV contract solicitation!

BREAKING NEWS...The Center for Military Medicine Research, McGowan Institute for Regenerative Medicine and our friends at University of Pittsburgh's Office of Industry and Economic Partnerships, Office of Sponsored Programs and University of Pittsburgh School of Pharmacy's Program Evaluation and Research Unit (PERU) would like to announce that University of Pittsburgh was selected as one of the 56 prime contractors for the Defense Health Agency's Omnibus IV contract! This is a 5-year with a 5-year renewal with a total potential award (for the whole program) of up to $10 billion!

There are 4 Market Segments: Research and Development, Research and Development, Regulatory Processes and Translational Sciences Support and Services. University of Pittsburgh is a prime offeror for Research and Development and Translational Sciences Support and Services.

Thank you to the team members who spent over 6 months putting together two winning proposals!

See the announcement below from Washington Technology.

https://washingtontechnology.com/contracts/2022/05/dha-awards-10b-military-medical-research-contract/367020/

The Defense Health Agency lists the University of Pittsburgh on the contract status page below.

https://www.defense.gov/News/Contracts/Contract/Article/3033240/#1DLAContract05162022

GOVCON Wire has an official announcement about Omnibus IV recipients.

https://www.govconwire.com/2022/05/dha-picks-56-for-10b-military-medical-randd-contract/